prodchem
Aug 13, 2026
Replimune's Tudriqev provides one of the most unusual FDA approval stories of 2026.
The treatment, formerly known as RP1 or vusolimogene oderparepvec, ultimately received accelerated FDA approval in August 2026 after the agency had issued two previous complete-response decisions. The latest approval therefore came on the third regulatory submission, making the case a useful benchmark for tracking unusually difficult FDA approval journeys during the 2026 drug-approval cycle.
The saga is particularly notable because the FDA's concerns were not simply administrative. Regulators repeatedly questioned whether the available clinical data could establish substantial evidence of effectiveness, particularly because the pivotal evidence came from a single-arm study and the treatment was administered alongside Bristol Myers Squibb's nivolumab, marketed as Opdivo.
Tudriqev's eventual approval therefore provides a valuable case study in how a contentious regulatory review can evolve from repeated rejection to eventual approval.
Most FDA approval processes do not attract attention because an application is repeatedly rejected before eventually succeeding.
Replimune's case stands out because the company had to navigate multiple rounds of regulatory scrutiny before receiving approval.
The sequence can be summarized as:
First FDA rejection: July 2025
Second FDA rejection: April 2026
Third submission: 2026
FDA advisory committee: 10–3 vote supporting the treatment's clinical meaningfulness
Final accelerated approval: August 2026
That makes two prior FDA rejections and three total submissions the central intelligence statistic behind this approval saga.
The FDA issued a complete-response letter to Replimune on July 21, 2025.
The agency concluded that it could not grant approval because of deficiencies in the clinical evidence supporting vusolimogene oderparepvec in combination with nivolumab for patients with unresectable advanced cutaneous melanoma.
The FDA specifically highlighted concerns surrounding the design of the RPL-001-16 Phase 2 trial.
The study was:
Single-arm
Phase 2
Conducted in combination with nivolumab
Focused on advanced melanoma patients
Based on response-rate comparisons rather than a randomized control group
Those characteristics created difficulties for regulators attempting to determine how much of the observed response could be attributed specifically to RP1.
The absence of a randomized control group became one of the most important issues in the FDA's review.
Without a control arm, regulators have less ability to determine whether observed outcomes are caused by the investigational treatment, the accompanying therapy, patient characteristics or other factors.
The FDA stated that the RPL-001-16 study was not considered an adequate and well-controlled clinical investigation providing substantial evidence of effectiveness.
This issue remained central even after additional data were submitted.
Tudriqev was being evaluated in combination with nivolumab, Bristol Myers Squibb's immune-checkpoint inhibitor.
That created another layer of regulatory complexity.
The FDA argued that the available study design made it difficult to isolate the contribution of vusolimogene oderparepvec from nivolumab.
In other words, even if patients responded, regulators wanted stronger evidence showing what portion of the benefit was attributable to RP1 itself.
That question became one of the defining issues throughout the approval process.
Replimune submitted additional material after the initial rejection.
However, the FDA issued another complete-response letter on April 10, 2026.
The agency said it had reanalyzed data from the RPL-001-16 study and reviewed additional data from the RP1-104 study. Even after those additional analyses, FDA reviewers concluded that the evidence remained insufficient to establish substantial evidence of effectiveness.
This represented the second major regulatory setback.
The April 2026 complete-response letter is particularly important because it shows that FDA's concerns were not simply new objections appearing late in the process.
The agency said its advice had remained consistent through communications dating back to March 2021.
That indicates that the core regulatory issue was evidence quality rather than a sudden change in the review standard.
The FDA identified several problems with the clinical evidence.
For RPL-001-16, the agency cited:
Difficulty isolating RP1's contribution when combined with nivolumab
Heterogeneity within the study population
Uncertainty surrounding response assessments
Potential confounding from surgical interventions
These issues made it harder for regulators to determine the treatment's independent clinical effect.
Despite the second rejection, Replimune continued pursuing approval.
The company eventually submitted the treatment for a third FDA review.
This third attempt became the decisive stage of the regulatory process.
Instead of ending with another complete-response letter, the process moved toward an FDA advisory committee discussion and ultimately accelerated approval.
Featured Product
An FDA advisory committee voted 10–3 in favor of the clinical significance of the treatment's data.
The vote did not legally bind the FDA, but it represented an important change in the regulatory narrative.
After repeated concerns over trial design and effectiveness, the committee concluded that the available evidence was sufficiently meaningful to support the treatment's potential benefit for this difficult-to-treat patient population.
The 10–3 vote is important precisely because it was not unanimous.
Several committee members continued to question the reliability of the available evidence.
That means the final approval did not emerge from a completely settled scientific debate.
Instead, the regulatory process remained contentious almost until the final decision.
On August 6, 2026, the FDA approved Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma following progression on an anti-PD-1-based regimen.
The approval marked Replimune's first approved product.
That makes the regulatory journey particularly consequential for the company.
After years of development and two previous FDA rejections, Replimune finally reached the commercial stage.
Tudriqev received accelerated approval rather than conventional full approval.
That distinction matters.
Accelerated approval allows the FDA to approve certain treatments based on evidence supporting an endpoint that is reasonably likely to predict clinical benefit, particularly when there is an unmet medical need.
The company must then provide confirmatory evidence.
Replimune has an ongoing late-stage confirmatory study.
The company expects data from that study around 2030.
This means the regulatory story is not completely finished.
The August 2026 decision provides market access, but continued approval depends on subsequent evidence confirming clinical benefit.
Reuters reported that the treatment produced tumor reduction or elimination in approximately 24.2% of patients, with a median response duration of 14.1 months.
Those results helped support the case for approval despite the previous concerns around trial design.
The response duration was particularly relevant because regulators and clinical experts were evaluating not only whether tumors responded, but whether those responses were sufficiently meaningful for patients with difficult-to-treat melanoma.
Tudriqev is a genetically modified herpes virus that is injected directly into tumors.
The treatment is designed to destroy tumor cells locally while also stimulating an immune response against cancer.
That mechanism differentiates it from systemic therapies that rely primarily on intravenous administration.
The approval covers patients with advanced cutaneous melanoma whose tumors progressed after previous anti-PD-1-based treatment.
This is a particularly challenging patient population because treatment options become more limited after resistance to immune-checkpoint therapy.
That unmet need was an important consideration in the eventual regulatory discussion.
Replimune's approval illustrates the tension between two regulatory priorities:
Evidence quality versus unmet medical need.
The FDA had repeatedly raised concerns about whether the clinical evidence met the traditional standard.
At the same time, patients with refractory melanoma have limited options.
The final accelerated approval demonstrates how regulators can weigh those considerations within an accelerated pathway.
A complete-response letter does not necessarily mean a drug's development program is finished.
Companies can:
Address FDA deficiencies
Submit additional data
Conduct additional analyses
Modify applications
Engage with advisory committees
Resubmit applications
Replimune ultimately used that process to move from two rejected reviews to an approval.
The company's experience is notable because the same central evidence concerns persisted through multiple stages.
Rather than simply fixing an administrative deficiency, Replimune had to defend the clinical relevance of its data.
That makes the case more useful as an intelligence benchmark for understanding difficult FDA approval pathways.
Very High significance
The FDA issued complete-response decisions in July 2025 and April 2026.
Very High significance
The third regulatory attempt ultimately resulted in approval.
High significance
The vote provided external support for the clinical meaningfulness of the treatment's data.
Very High significance
The FDA ultimately allowed commercial access while requiring confirmatory evidence.
High significance
Future results will determine whether the evidence supporting continued approval is ultimately strengthened.
The most useful intelligence statistic from the case is straightforward:
FDA rejections before approval: 2
Total submissions leading to approval: 3
That makes Tudriqev a particularly notable 2026 example of a drug moving through repeated regulatory setbacks before eventually reaching the market.
However, it would be misleading to claim that it represents a unique event in all FDA history. Drugs have been rejected and later approved after additional submissions before.
Its significance comes from the combination of repeated rejection, persistent evidence concerns, advisory-committee scrutiny and eventual accelerated approval within the same development saga.
The Tudriqev story highlights the importance of trial design.
A promising response rate may not be sufficient when regulators cannot confidently determine:
What caused the response
Whether the comparison population is appropriate
Whether patient populations are sufficiently comparable
Whether response assessments are reliable
Whether combination therapies create attribution problems
For developers, these issues can become as important as the headline efficacy number.
A strong clinical program can potentially shorten the path to approval.
Conversely, weaknesses in study design can lead to:
Complete-response letters
Additional analyses
Delayed submissions
Advisory committee meetings
Additional clinical studies
Higher development costs
Replimune's experience demonstrates how those consequences can accumulate.
The FDA's complete-response letters demonstrate that the agency's concerns had been communicated repeatedly.
For pharmaceutical developers, this emphasizes the value of early regulatory engagement.
Companies need to understand not only whether their data look positive, but whether the study design answers the specific questions regulators will ask.
The August approval does not eliminate regulatory risk.
Investors should monitor:
Confirmatory trial enrollment
Confirmatory efficacy results
Duration of response
Safety data
Commercial launch performance
Physician adoption
Reimbursement
Competitive melanoma therapies
FDA post-approval requirements
The confirmatory trial will ultimately be one of the most important milestones.
Reuters reported that the average therapy course is expected to cost approximately $450,000, with shipments expected to begin roughly 60 days after approval.
That creates substantial commercial potential, but actual revenue will depend on:
Patient eligibility
Hospital adoption
Reimbursement
Treatment-center capacity
Competitive therapies
Real-world clinical outcomes
The commercial story therefore remains separate from the regulatory victory.
Tudriqev becomes another option for patients with advanced melanoma who have exhausted earlier treatment approaches.
Reuters noted that it competes with Amtagvi, Iovance Biotherapeutics' melanoma treatment approved in 2024.
The difference in treatment approach could become an important factor in physician and patient decisions.
Replimune's experience provides several practical lessons.
Companies pursuing difficult regulatory approvals should:
Design controlled studies whenever feasible
Clearly isolate the contribution of combination therapies
Minimize patient-population heterogeneity
Establish robust response-assessment methods
Engage regulators early
Address complete-response deficiencies systematically
Prepare confirmatory evidence early
The case demonstrates that a strong scientific rationale alone may not overcome weaknesses in the evidentiary framework.
The Tudriqev saga is particularly relevant to the broader 2026 FDA environment because it demonstrates how regulatory decisions can evolve.
The sequence moved from:
Rejection → additional evidence → rejection → advisory review → approval
That is a useful framework for understanding other contentious FDA approval stories.
Replimune's Tudriqev now provides one of the clearest regulatory case studies of 2026.
The FDA rejected the application twice—first in July 2025 and again in April 2026—before the company succeeded with its third submission.
The final approval followed a 10–3 advisory committee vote and came through the accelerated-approval pathway.
The story is therefore more complicated than simply "FDA rejected the drug twice and then changed its mind."
The agency's concerns centered on evidence quality, including the single-arm study design, patient heterogeneity and difficulty separating RP1's contribution from nivolumab.
Ultimately, the combination of additional data, continued regulatory engagement, advisory input and the unmet need in refractory melanoma moved the treatment across the approval threshold.
The next test will be the confirmatory study. If that evidence validates clinical benefit, Tudriqev's unusual approval journey could become an important example of how a contentious FDA review can ultimately lead to successful market authorization.
Tudriqev was rejected by the FDA twice before receiving approval.
The first complete-response decision came in July 2025.
The second came in April 2026.
The treatment succeeded on its third regulatory submission.
An FDA advisory committee voted 10–3 in favor of the clinical meaningfulness of the available data.
Tudriqev ultimately received accelerated approval in August 2026.
FDA concerns focused heavily on the single-arm study, combination therapy and uncertainty around treatment attribution.
A confirmatory Phase 3 study remains ongoing, with results expected around 2030.
The case provides a useful benchmark for unusually contentious FDA approval pathways.
The regulatory story remains incomplete until confirmatory evidence establishes continued clinical benefit.
Found this useful?
Continue Reading
Tudriqev's approval rests on tumor response data rather than confirmed survival benefit, leaving the therapy under ongoing regulatory watch until Phase 3 trial results arrive in 2027. History shows that outcome is far from guaranteed, a factor worth weighing for anyone tied to its manufacturing supply chain.
TPC's polyisobutylene and C4 derivatives portfolio gives Eneos a strategic foothold in specialty petrochemicals in the US. The business adds a differentiated growth platform beyond traditional refining.
Explore how Replimune's Tudriqev overcame two FDA rejections to secure approval and why its unusual regulatory journey could become a benchmark for 2026 drug-development strategy.
